Bibliography
- HUGHES B, OWENS R, PERRY M, WARRELLOW G, ALLEN R: PDE 4 inhibitors: the use of molecular cloning in the design and development of novel drugs. Drug Disc. To-day (1997) 2(3):89–101.
- ••Excellent review article with chemical structures of impor-tant inhibitors.
- TORPHY TJ: Phosphodiesterase isozymes: molecular targets for novel antiasthma agents. Am. J. Respir. Grit. Care Med. (1998) 157:351–370.
- ••Excellent review article with focus on asthma.
- BURNOUF C, PRUNIAUX M, SZILAGYI CM: Chapter 10. Phosphodiesterase 4 inhibitors. In: Annual Reports in Medicinal Chemistry (Volume 33). Bristol JA (Ed.), Aca-demic Press, San Diego (1998):91–109.
- •Good source of inhibitor structures.
- CHRISTENSEN SB, BARNETTE MS, UNDERWOOD DC etal.: The evolution of ariflo (SB-207499), a second gen-eration PDE4 inhibitor for the treatment of asthma and COPD. 217th ACS National Meeting. Anaheim, USA (1999). MEDI–269.
- HARBINSON PL, MACLEOD D, HAWKSWORTH S et al.:The effect of a novel orally-active selective PDE4 inhibitor (CDP840) on allergen-induced responses in asthmatic subjects. Eur. Respk. J. (1997) 10:1008–1014.
- MULLER T, ENGELS P, FOZARD JR: Subtypes of the Type 4cAMP phosphodiesterases: structure, regulation and selective inhibition. Trends Pharmacol. ScL (1996) 17:294–298.
- ALVAREZ R, SETTE C, YANG D et al.: Activation and selec-tive inhibition of a cyclic AMP-specific phosphodies-terase, PDE-4D3. Mol. Pharmacol. (1995) 48:616–622.
- VINICK FJ, SACCOMANO NA, KOE BK eta].: Nicotinamide ethers: novel inhibitors of calcium-independent phos-phodiesterase and [3H]rolipram binding. J. Merl. Chem. (1991) 34(0:86–89.
- •Early work by Pfizer on the preparation of examples of this structural class for CNS activity.